Market of biomarkers is currently going through a major growth. The drive for that is the demand of biomarker based drug development and diagnosis. To fulfill this demand numerous companies and research facilities have been joining their forces to provide novel platforms in metabolomics, proteomics, and transcriptomics.

Nowadays we can also observe a trend of supporting biomarkers market from government agencies worldwide, including the US FDA, as well as from pharmaceutical companies.